Scientific and Laboratory Management – Technical/Scientific

Job type: Full-Time
Accepting BioReady™: Yes
Category: Research and Development
Salary: not disclosed
Location: Montreal, QC
Posted: March 4, 2019
Ends: April 4, 2019

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.
The following are minimum qualifications:

  • Development, optimization and use of flow cytometry assays, immunoassay techniques (ELISAs, ECLs, Luminex), cell-based assays, (ELIspot, bioassays, etc.), qPCR and RT-qPCR.
  • Design assays fit to the need of the sponsors
  • Design assays to support the development of animal models in the immunology/inflammation field
  • Write scientific documents, correct and review the results.
  • Analyze scientific problems, troubleshoot analytical methods and technical issues and interpret the raw data.
  • Responsible for the management of the scientific project and for the conduct of the experiments in the laboratory

We are seeking a candidate who primarily has an immunology background as well as:

  • Has flow cytometry and immunoassay experience.
  • Possess a PhD in Immunology or have relevant experience.
  • Strong skills in method development
  • Possess a PhD in Immunology or have relevant experience.
  • Possess a PhD in Immunology or have relevant experience.
  • Communicates effectively
  • Is computer literate (Microsoft Word and Excel) and possess excellent communication, interpersonal and teamwork abilities.
  • Is fluent in French and English

 To apply for this job, please click here.
About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 13,000 employees within 80 facilities in 23 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 80% of the drugs approved by the FDA in 2017.